GLPG: Galapagos N.V. Price-to-Revenue Multiple

Symbol and logo of brand Galapagos Genomics (GLPG)

Geopolitical instability and sanctions are hindering global clinical trials for new drugs, a trend reflected in the price action of Galapagos NV (GLPG). The EV/Revenue multiple clearly demonstrates the current market valuation, with the latest reading standing at 1.40. Business resilience is supported by the diversification of European plants, while the strategic focus is shifting toward decentralized CAR-T therapy production for oncology clinics.

Price-to-Revenue Ratio: glpg.com (GLPG) for 07/04/2022 - 05/08/2026

Metric breakdowns and analytics for Galapagos Genomics (GLPG)

- share price and consensus valuation forecast:
Price Performance Chart glpg.com|GLPG - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Galapagos Genomics|GLPG - Enterprise Value
- book capitalization data:
Book Value per Share Galapagos|GLPG - Company Book Value|Market Value to Book Value Ratio glpg.com|GLPG - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Galapagos NV|GLPG - Long-Term Debt to Equity|Current Liabilities to Equity Galapagos Corp|GLPG - Company Aggregate Debts|Debts to Book Capitalization Galapagos Genomics|GLPG - Company Long-Term Debts|Short-Term Indebtedness Galapagos|Immediate Liquidity glpg.com
- company profitability and valuation multiples indicators:
GLPG - Company Net Income|Company Profit Forecast Galapagos NV|GLPG - Price to Earnings Ratio|Future Price to Earnings Multiple Galapagos N.V.|GLPG - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Galapagos Genomics|GLPG - Operating profit before deduction of amortization|Earnings per share for the last twelve months Galapagos|GLPG - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year glpg.com|GLPG - Earnings per share growth in current year|Net earnings per share growth forecast for next year Galapagos NV
- total revenue and sales volume data:
GLPG - Company Revenue|Company Expected Revenue glpg.com|GLPG - P/S Multiple|Projected Price to Revenue Galapagos Genomics
General company analysis:GLPG glpg.com
Signature product of Galapagos N.V.

To filter for fundamentally resilient assets, investors compare market capitalization against actual cash flows from sales. This ratio determines the cost per unit of revenue, which is critical for Galapagos NV (GLPG), as the company delegates production and research to contractors to reduce capital expenditures; consequently, the P/S trajectory allows for an objective assessment of the efficiency of this outsourcing model relative to the market price.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|Price-to-Revenue Multiple Verona Pharma PLC|Jyong Biotech Corp - P/S Multiple|LGND - P/S Multiple|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|PRGO (perrigo.com) - Price-to-Revenue Ratio|ALVO (Alvotech SA) - P/S Multiple|P/S Multiple Liquidia Corp|Price-to-Revenue Ratio ANI Pharma (ANIP)|MNKD: Price-to-Sales Ratio|P/S Multiple AMPH (Amphastar Pharmaceuticals)|P/S Multiple pacira.com PCRX|ARS Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Multiple Theravance Biopharma Inc (TBPH)|Aquestive Pharma (AQST) - Price-to-Revenue Ratio|Price to Sales scPharmaceuticals (SCPH)|Price-to-Revenue Ratio Tectonic Therapeutic Inc.|tonixpharma.com (TNXP) - Price-to-Revenue Coefficient|Market Cap to Revenue SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio BioHarvest BHST|EXOZ: Market Cap to Revenue Ratio|ORMP: Market Cap to Revenue|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Price-to-Revenue Multiple ABVC BioPharma Inc. ABVC|Price-to-Revenue Ratio Cumberland Pharma|Price-to-Revenue Ratio QNTM|Price-to-Revenue Ratio FibroGen, Inc. (FGEN)|TELO: Price-to-Sales Ratio|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|Price-to-Revenue Multiple Synergy CHC Corp.|RLYB - Price-to-Revenue Ratio|Price-to-Sales Ratio LEXX|PULM: P/S Multiple|Pheton Holdings - Market Capitalization-to-Revenue Ratio|APM (Aptorum Group Ltd) - P/S Multiple|P/S Multiple Lyra Therapeutics Inc.|Price-to-Revenue Ratio Impact BioMedical (IBO)|TNFA (tnfpharma.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio cbdMD YCBD|PRFX - Market Cap to Revenue|Auris Medical - P/S Multiple|LIPO - P/S Multiple|OPTN (Optinose) - Market Cap to Revenue|Pieris Pharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Procaps Group S.A.|Price to Sales petrospharma.com PTPI|Market Cap to Revenue QLI (Qilian International Holding)|Market Cap to Sales Volume SLRN|P/S Multiple TFFP (TFF Pharma)